Sign in
Taking people in FrancePhase 4

Zoledronic acid timing after denosumab in postmenopausal osteoporosis

Compares two zoledronic acid schedules after stopping denosumab in women with osteoporosis.

Key facts

Who runs it
Centre Hospitalier Universitaire De Toulouse
Where
Amiens Cedex 1, Bayonne, Bordeaux, Cahors, Dax, Le Mans Cedex 9, Limoges, Marseille, Montpellier Cedex 5, Nice, Orleans Cedex 2, Paris, Paris Cedex 10, Perpignan Cedex, Poitiers, Rennes, Saint-Priest-en-Jarez, Toulouse, and Toulouse Cedex 9, FranceSee the 19 sites
Registry title
Strategies for zoledronic acid post-denosumab discontinuation in postmenopausal osteoporosis
Status
Recruiting
Phase
Phase 4
People taking part
200 people, planned
Started
2 Oct 2025
Expected to end
1 Apr 2029
Type of study
Interventional
Record updated
26 June 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for women with post-menopausal osteoporosis who have taken denosumab for at least 2 years and are stopping it because the treatment goal was reached.

Age
18 years or older
Sex
Women only
Disease stage
Post-menopausal osteoporosis. A history of severe fracture, or a T-score of −2.5 or lower at the femur or lumbar spine before starting denosumab.
Earlier treatment
Must have had denosumab for at least 2 years, with no fracture in the last 2 years, no new risk factors, and no bone density drop above 0.03 g/cm² at the spine or hip. Must not have used other bone-active medicines in the last year.

Main reasons for not taking part

  • Bone disease other than post-menopausal osteoporosis
  • Liver failure or uncontrolled hormone diseases
  • Cancer not in remission for at least 5 years
  • Kidney disease with filtration rate below 35 mL/min, low blood calcium, or past intolerance to a bisphosphonate
  • Ongoing systemic glucocorticoid treatment, or a non-healed jaw injury

The registry criteria, word for word

Show all 18 criteriaShow less

Who can take part

  • Women aged ≥ 18 years
  • With post-menopausal osteoporosis AND treated with denosumab for at least 2 years
  • With post-menopausal osteoporosis - AND reaching decision of denosumab withdrawal because of achieved therapeutic target defined as no fracture during the last 2 years of treatment; no new risk factors; no BMD decrease > 0.03 g/cm² at the spine or hip
  • With post-menopausal osteoporosis - AND with a history of severe fracture OR a femoral or a lumbar T-score ≤ −2.5 prior denosumab initiation
  • Free, informed and written consent signed by the participant and the investigator (at the latest on the day of inclusion and before any examination required by the research)
  • Person affiliated or beneficiary of the French social security scheme

Who cannot take part

  • Ongoing treatment with systemic glucocorticoids. However, substitutive treatment with hydrocortisone (20-30 mg/per day) is tolerated
  • Daily systemic glucocorticoids ≥ 7.5 mg prednisone-equivalent used for at least 3 months, and stopped less than 3 months prior inclusion
  • Contra-indication to bisphosphonates according to license recommendation including: o Chronic kidney disease with Glomerular filtration rate stage > or = G3b (<35 mL/min) o Prior intolerance to zoledronic acid or another bisphosphonate o Hypocalcemia
  • Bone disease other than post-menopausal osteoporosis, including metabolic bone disease
  • Uncontrolled endocrine diseases
  • Liver failure
  • Cancer not in remission for at least 5 years. Chronic asymptomatic hemopathies not requiring treatment are tolerated (e.g., asymptomatic Binet stage A chronic lymphocytic leukaemia, etc.)
  • Use of medication affecting bone metabolism during the last year: bisphosphonates, teriparatide, romosozumab, hormone replacement therapy, selective Estrogen receptor modulators, breast cancer hormonotherapy
  • Subjects unable to give an informed consent or to fill the case report form
  • Subjects under law protection
  • Foreseeable poor compliance with the strategy, alcoholism, toxicomania
  • Patients with non-healed jaw injury

Where in France

  • Centre Hospitalier Universitaire Amiens PicardieAmiens Cedex 1, FranceTaking people
  • Centre Hospitalier de la Cote BasqueBayonne, FranceTaking people
  • Centre hospitalier Universitaire de BordeauxBordeaux, FranceTaking people
  • Centre Hospitalier Jean RougierCahors, FranceTaking people
  • Centre Hospitalier De Dax Cote D'ArgentDax, FranceTaking people
  • Centre Hospitalier Le MansLe Mans Cedex 9, FranceTaking people
  • Centre Hospitalier Et Universitaire de LimogesLimoges, FranceTaking people
  • Centre Hospitalier Regional De MarseilleMarseille, FranceTaking people
  • Centre Hospitalier Universitaire De MontpellierMontpellier Cedex 5, FranceTaking people
  • Centre Hospitalier Universitaire de NiceNice, FranceTaking people
  • Centre Hospitalier Universitaire D OrleansOrleans Cedex 2, FranceTaking people
  • Assistance Publique Hopitaux de ParisParis, FranceTaking people
  • Assistance Publique Hopitaux De ParisParis Cedex 10, FranceTaking people
  • Centre Hospitalier De PerpignanPerpignan Cedex, FranceTaking people
  • Universite De PoitiersPoitiers, FranceTaking people
  • Centre Hospitalier Universitaire de RennesRennes, FranceTaking people
  • Centre Hospitalier Universitaire de Saint EtienneSaint-Priest-en-Jarez, FranceTaking people
  • Centre Hospitalier Universitaire de ToulouseToulouse, FranceTaking people
  • Centre Hospitalier Universitaire De ToulouseToulouse Cedex 9, FranceTaking people

About the trial

What the trial wants to find out

To compare the 1-year lumbar clinical and densitometric efficacy of biomarkers-driven ZOL treatment vs standardized ZOL treatment after denosumab withdrawal in post-menopausal osteoporosis

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record

Print a page for my doctor

Data and sources

Registry record
Listed on the EU's official list of trials (CTIS).How to verify a trial in the registry
Official title
Strategies for zoledronic acid post-denosumab discontinuation in postmenopausal osteoporosis
Plain-language title
Zoledronic acid timing after denosumab in postmenopausal osteoporosisGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 9 November 2026.
Record updated
26 June 2026